MONMOUTH JUNCTION, N.J.,
July 30, 2021 /PRNewswire/ --
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the
treatment of life-threatening conditions in intensive care and
cardiac surgery using blood purification via its proprietary
polymer adsorption technology, announces the successful completion
of its MISSION 100,000 international fundraising campaign to fight
the spread of COVID-19, raising $100,000 to benefit the global, not-for-profit
humanitarian organization, CARE. The funds raised for CARE's
Crisis Response Campaign enable the organization to provide various
vaccination, education, sanitation, and disinfectant initiatives
around the world to prevent the spread of COVID-19.
CytoSorbents will present CARE its donation at the Opening Bell
ceremony at NASDAQ later this morning.
CytoSorbents successfully raises $100,000 for global humanitarian organization
CARE to fight the spread of COVID-19
The campaign commemorates a major Company milestone achieved
last year of cumulatively shipping more than 100,000 CytoSorb®
blood purification cartridges worldwide to treat deadly
inflammation, such as seen in severe COVID-19 infection. That
number has since grown to more than 131,000 cartridges, including
those used to treat more than 6,000 COVID-19 patients across more
than 30 countries, including the U.S.
Dr. Phillip Chan, Chief Executive
Officer of CytoSorbents stated, "On behalf of the Company, I would
like to thank all of our friends, business partners, colleagues,
employees, and shareholders for your generous donations, enabling
us to match your support and fullfill our pledge to raise
$100,000 to support CARE's COVID-19
Emergency Fund. With the rise in new COVID-19 cases caused by new
highly contagious coronavirus variants, these funds will no doubt
be put to good use. We are proud to support CARE and the
global fight against the COVID-19 pandemic in communities here in
the U.S., in Europe, and
worldwide."
Michelle Nunn, CARE USA President and CEO stated, "As COVID has
impacted the lives of hundreds of millions of marginalized people
around the world, CARE's life-saving work has never
been more important. We want to thank our partners at
CytoSorbents for contributing and raising funds for CARE's Crisis
Response Campaign, helping ensure access to personal protective
equipment, medical care, and health education to prevent and slow
COVID's spread. Getting past this pandemic is going to take all of
us uniting in a global effort, and corporate partnerships like this
help demonstrate we're in this together."
CARE is making a positive difference in the
COVID-19 pandemic
For 75 years, CARE has worked around the globe to save
lives, defeat poverty, achieve social justice, and create better
lives for many of the world's most vulnerable people. CARE's Crisis
Response Campaign continues to play a central role in combating the
pandemic, providing vaccine access, clean water, food, financial
assistance, disease prevention education, hand washing stations,
and care packages, consisting of masks, soap, detergent, water
canisters, and disinfectant to families, emergency shelters, and
refugee camps across 69 countries to date. In addition, the Fund
has financed mass media campaigns reaching nearly 216 million
people with information on COVID-19 prevention and services,
including public service announcements encouraging
vaccination.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of
life-threatening conditions in intensive care and cardiac surgery
using blood purification. Its flagship product, CytoSorb® is
approved in the European Union with distribution in 68 countries
around the world, as an extracorporeal cytokine adsorber designed
to reduce the "cytokine storm" or "cytokine release syndrome" seen
in common critical illnesses that may result in massive
inflammation, organ failure, and patient death. These are
conditions where the risk of death can be extremely high, yet few
to no effective treatments exist. CytoSorb is also being used
during and after cardiac surgery to remove inflammatory mediators
that can lead to post-operative complications, including multiple
organ failure. More than 131,000 CytoSorb devices have been
delivered to date. CytoSorb was originally introduced into the
European Union under CE-Mark as a first-in-kind cytokine adsorber.
Additional CE-Mark label expansions were received for the removal
of bilirubin and myoglobin in clinical conditions such as liver
disease and trauma, respectively, and both ticagrelor and
rivaroxaban during cardiothoracic surgery. CytoSorb has also
received FDA Emergency Use Authorization in the United States for use in critically ill
COVID-19 patients with imminent or confirmed respiratory
failure. CytoSorbents' technology has also been granted FDA
Breakthrough Designation for the removal of ticagrelor in a
cardiopulmonary bypass circuit during emergent and urgent
cardiothoracic surgery, and if FDA marketing approval is obtained,
would be marketed as DrugSorb-ATR™ in the
United States.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. Its technologies have received non-dilutive
grant, contract, and other funding of more than $39.5 million from DARPA, the U.S. Department of
Health and Human Services (HHS), the National Institutes of Health
(NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S.
Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM),
Air Force Material Command (USAF/AFMC), and others. The Company has
numerous marketed products and products under development based
upon this unique blood purification technology protected by many
issued U.S. and international patents and registered trademarks,
and multiple patent applications pending, including ECOS-300CY®,
CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®,
K+ontrol™, DrugSorb™, DrugSorb-ATR™, ContrastSorb, and
others. For more information, please visit the
Company's websites at www.cytosorbents.com and www.cytosorb.com or
follow us on Facebook and Twitter.
About CARE
Founded in 1945 with the creation of the CARE Package®, CARE is
a leading humanitarian organization fighting global poverty. CARE
places special focus on working alongside poor girls and women
because, equipped with the proper resources, they have the power to
lift whole families and entire communities out of
poverty. Last year, CARE worked in over 100 countries,
reaching more than 90 million people through 1,300
projects. To learn more, visit www.care.org.
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as "may," "should," "could,"
"expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" and similar words, although some
forward-looking statements are expressed differently. You should be
aware that the forward-looking statements in this press release
represent management's current judgment and expectations, but our
actual results, events and performance could differ materially from
those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to,
the risks discussed in our Annual Report on Form 10-K, filed with
the SEC on March 9, 2021, as updated
by the risks reported in our Quarterly Reports on Form 10-Q, and in
the press releases and other communications to shareholders issued
by us from time to time which attempt to advise interested parties
of the risks and factors which may affect our business. We caution
you not to place undue reliance upon any such forward-looking
statements. We undertake no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise, other than as required
under the Federal securities laws.
Please Click to Follow Us on Facebook and Twitter
CytoSorbents Investor Relations Contact:
Terri Anne Powers
Vice President of Investor Relations and Corporate
Communications
732-482-9984
tpowers@cytosorbents.com
CytoSorbents Public Relations Contact:
Eric Kim
Rubenstein Public Relations
212-805-3052
ekim@rubensteinpr.com
CARE USA
Contact:
Rachel Kent
Senior Press Officer
516-270-8911
rachel.kent@care.org
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cytosorbents-completes-its-mission-100-000-international-fundraising-campaign-to-fight-the-spread-of-covid-19-for-global-humanitarian-organization-care-301344915.html
SOURCE CytoSorbents Corporation